Drug Profile
Icanbelimod - Suzhou Connect Biopharmaceuticals
Alternative Names: CBP-307Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Suzhou Connect Biopharmaceuticals
- Class Amines; Anti-inflammatories; Carboxylic acids; Cyclobutanes; Fluorobenzenes; Oxadiazoles; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Crohn's disease; Ulcerative colitis
Highest Development Phases
- Phase II Crohn's disease; Ulcerative colitis
- Phase I Autoimmune disorders
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO, Capsule)
- 01 Jun 2023 Efficacy and adverse events data from a phase II trial in Ulcerative colitis released by Connect Biopharma
- 10 Nov 2022 Suzhou Connect Biopharmaceuticals completes a phase-II trial in Ulcerative colitis in Ukraine, USA, China, Pakistan (PO) (NCT04700449)